382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles European Journal of Obstetrics & Gynecology and Reproductive Biology Year : 2022

382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure

Domains

Life Sciences [q-bio]

Christine Dupuis  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-04045112

Submitted on : Friday, March 24, 2023-3:53:56 PM

Last modification on : Sunday, March 26, 2023-3:36:38 AM

Not file

Dates and versions

inserm-04045112 , version 1 (24-03-2023)

Identifiers

Cite

E. Bautrant, C. Lévêque, M. Santos, J. Kouame, O. Franké, et al.. 382 PHASE-III Randomized monocentric controlled trial comparing clinical and cost-effectiveness analysis of botulinum toxin uterine injections versus placebo for severe dysmenorrhea and chronic pelvic pain from uterine origin after standard therapeutic failure. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2022, 270, pp.e102-e103. ⟨10.1016/j.ejogrb.2021.11.333⟩. ⟨inserm-04045112⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM UNIV-AMU U1252
4 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More